Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes

Discovery Medicine

Volumn 18, Issue 101, 2014, Pages 301-311

  Zhang, Xu ^a,b   Jia, Haiying ^c,d   Lu, Yao ^a,b   Dong, Chengliang ^c   Hou, Jinghui ^e   Wang, Zheng ^f   Wang, Feng ^b   Zhong, Hongbin ^b   Wang, Lin ^f   Wang, Kai ^c  

^a SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

^b BGI Diagnosis Tianjin ^*  (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; MUCIN 2; MN1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARID1B GENE; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; DNA FRAGMENTATION; DNA LIBRARY; EXOME; FEMALE; GENE; GENE MUTATION; GENE SEQUENCE; HIGH THROUGHPUT SEQUENCING; HUMAN; MALE; MALIGNANT MENINGIOMA; MALIGNANT TRANSFORMATION; MENINGIOMA 1 GENE; MIDDLE AGED; MISSENSE MUTATION; MUCIN 2 GENE; NEUROFIBROMATOSIS TYPE 2 GENE; PATHOGENESIS; POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEMA4D GENE; SEQUENCE ALIGNMENT; SOMATIC MUTATION; TUMOR INVASION; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 7 GENE; VALIDATION STUDY; GENETICS; MENINGIOMA; MUTATION; TUMOR SUPPRESSOR GENE;

EXOME; FEMALE; GENES, NEUROFIBROMATOSIS 2; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MUTATION; TUMOR SUPPRESSOR PROTEINS;

EID: 84930618444     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Aavikko M, Li SP, Saarinen S, Alhopuro P, Kaasinen E, Morgunova E, Li Y, Vesanen K, Smith MJ, Evans DG, Poyhonen M, Kiuru A, Auvinen A, Aaltonen LA, Taipale J, Vahteristo P. Loss of SUFU function in familial multiple meningioma. Am J Hum Genet 91(3):520-526, 2012.
2. Abramovich CM, Prayson RA. Apoptotic activity and bcl-2 immunoreactivity in meningiomas. Association with grade and outcome. Am J Clin Pathol 114(1):84-92, 2000.
3. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. Nat Methods 7(4):248-249, 2010.
4. Brastianos PK, Horowitz PM, Santagata S, Jones RT, Mckenna A, Getz G, Ligon KL, Palescandolo E, Van Hummelen P, Ducar MD, Raza A, Sunkavalli A, Macconaill LE, Stemmer-Rachamimov AO, Louis DN, Hahn WC, Dunn IF, Beroukhim R. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45(3):285-289, 2013.
5. Carstens C, Messe E, Zang KD, Blin N. Human KRAS oncogene expression in meningioma. Cancer Lett 43(1-2):37-41, 1988.
6. Ch'ng ES, Kumanogoh A. Roles of Sema4D and Plexin-B1 in tumor progression. Mol Cancer 9:251, 2010.
7. Chang X, Shi L, Gao F, Russin J, Zeng L, He S, Chen TC, Giannotta SL, Weisenberger DJ, Zada G, Wang K, Mack WJ. Genomic and transcriptome analysis revealing an oncogenic functional module in meningiomas. Neurosurg Focus 35(6):E3, 2013.
8. Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet 49(7):433-436, 2012.
9. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, Parsa AT, Yang I. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus 30(5):E6, 2011.
10. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. Genome Res 19(9):1553-1561, 2009.
11. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avsar T, Li J, Murray PB, Henegariu O, Yilmaz S, Gunel JM, Carrion-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioglu M, Kaymakcalan H, Caglayan AO, Sencar L, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339(6123):1077-1080, 2013.
12. Detta A, Kenny BG, Smith C, Logan A, Hitchcock E. Correlation of proto-oncogene expression and proliferation and meningiomas. Neurosurgery 33(6):1065-1074, 1993.
13. Dobbins SE, Broderick P, Melin B, Feychting M, Johansen C, Andersson U, Brannstrom T, Schramm J, Olver B, Lloyd A, Ma YP, Hosking FJ, Lonn S, Ahlbom A, Henriksson R, Schoemaker MJ, Hepworth SJ, Hoffmann P, Muhleisen TW, Nothen MM, et al. Common variation at 10p12.31 near MLLT10 influences meningioma risk. Nat Genet 43(9):825-827, 2011.
14. Fernandez HA, Kallenbach K, Seghezzi G, Grossi E, Colvin S, Schneider R, Mignatti P, Galloway A. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res 82(2):156-162, 1999.
15. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol 6(4):340-351, 2007.
16. Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat Med 9(6):669-676, 2003.
17. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39(Database issue):D945-D950, 2011.
18. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. A census of human cancer genes. Nat Rev Cancer 4(3):177-183, 2004.
19. Gao F, Ling C, Shi L, Commins D, Zada G, Mack WJ, Wang K. Inversion-mediated gene fusions involving NAB2-STAT6 in an unusual malignant meningioma. Br J Cancer 109(4):1051-1055, 2013a.
20. Gao F, Shi L, Russin J, Zeng L, Chang X, He S, Chen TC, Giannotta SL, Weisenberger DJ, Zada G, Mack WJ, Wang K. DNA methylation in the malignant transformation of meningiomas. PLoS One 8(1):e54114, 2013b.
21. Gutmann DH, Donahoe J, Perry A, Lemke N, Gorse K, Kittiniyom K, Rempel SA, Gutierrez JA, Newsham IF. Loss of DAL-1, a protein 4.1-related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 9(10):1495-1500, 2000.
22. Hamada T, Goto M, Tsutsumida H, Nomoto M, Higashi M, Sugai T, Nakamura S, Yonezawa S. Mapping of the methylation pattern of the MUC2 promoter in pancreatic cancer cell lines, using bisulfite genomic sequencing. Cancer Lett 227(2):175-184, 2005.
23. Huang Da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57, 2009.
24. Ichimura K, Mungall AJ, Fiegler H, Pearson DM, Dunham I, Carter NP, Collins VP. Small regions of overlapping deletions on 6q26 in human astrocytic tumours identified using chromosome 6 tile path array-CGH. Oncogene 25(8):1261-1271, 2006.
25. Imai Y, Yamagishi H, Fukuda K, Ono Y, Inoue T, Ueda Y. Differential mucin phenotypes and their significance in a variation of colorectal carcinoma. World J Gastroenterol 19(25):3957-3968, 2013.
26. Jagannathan J, Oskouian RJ, Yeoh HK, Saulle D, Dumont AS. Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature. Skull Base 18(3):173-187, 2008.
27. Kazumoto K, Tamura M, Hoshino H, Yuasa Y. Enhanced expression of the sis and c-myc oncogenes in human meningiomas. J Neurosurg 72(5):786-791, 1990.
28. Koboldt DC, Zhang Q, Larson DE, Shen D, Mclellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22(3):568-576, 2012.
29. Kumar P, HenikoffS, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4(7):1073-1081, 2009.
30. Lekanne Deprez RH, Riegman PH, Groen NA, Warringa UL, Van Biezen NA, Molijn AC, Bootsma D, De Jong PJ, Menon AG, Kley NA, Et Al. Cloning and characterization of MN1, a gene from chromosome 22q11, which is disrupted by a balanced translocation in a meningioma. Oncogene 10(8):1521-1528, 1995.
31. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25(14):1754-1760, 2009.
32. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25(16):2078-2079, 2009.
33. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97-109, 2007.
34. Mckenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, Depristo MA. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20(9):1297-1303, 2010.
35. Menon R, Deng M, Boehm D, Braun M, Fend F, Boehm D, Biskup S, Perner S. Exome Enrichment and SOLiD Sequencing of Formalin Fixed Paraffin Embedded (FFPE) Prostate Cancer Tissue. Int J Mol Sci 13(7):8933-8942, 2012.
36. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15(Suppl 2):ii1-56, 2013.
37. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer 85(9):2046-2056, 1999.
38. Pham MH, Zada G, Mosich GM, Chen TC, Giannotta SL, Wang K, Mack WJ. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus 30(5):E7, 2011.
39. Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jager N, Santarius T, Tarpey PS, Stephens PJ, et al. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125(3):351-358, 2013.
40. Ryken TC, Chamberlain M. Update on meningioma: neurosurgeon and medical neuro-oncologist perspective. Medscape Education Oncology. 2011.
41. Sausen M, Leary RJ, Jones S, Wu J, Reynolds CP, Liu X, Blackford A, Parmigiani G, Diaz LA, Jr., Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD. Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet 45(1):12-17, 2013.
42. Tang H, Jin X, Li Y, Jiang H, Tang X, Yang X, Cheng H, Qiu Y, Chen G, Mei J, Zhou F, Wu R, Zuo X, Zhang Y, Zheng X, Cai Q, Yin X, Quan C, Shao H, Cui Y, et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet 46(1):45-50, 2014.
43. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38(16):e164, 2010.
44. Whittle IR, Smith C, Navoo P, Collie D. Meningiomas. Lancet 363(9420):1535-1543, 2004.
45. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11(7):481-492, 2011.
46. Zhou H, Binmadi NO, Yang YH, Proia P, Basile JR. Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. Angiogenesis 15(3):391-407, 2012.